All In Biotech

Drug Trial Radar · NCT00633347

Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation

Last checked: Nov 19, 2026Latest source record: Feb 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 570 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

570

Actual

Start

Jan 2007

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIAAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 44 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Oocyte donation is a well established procedure in assisted reproduction treatments (ART). It is demonstrated that the use of hormonal substitution therapy, for the synchronization of the cycles between the recipients and the donors, provides good results, similar to the ones obtained with the natural cycle. In the patients - recipients with preserved ovarian function, the recipient's natural cycle is annulled, thus preventing the spontaneous Luteinizing Hormone surge. Simultaneously and while waiting for the suitable donor, her endometrium is prepared. When the donation occurs and fertilization with the husband sperm takes place, her cycle is stimulated again in order to synchronize her window of implantation with the donor's ovulation. Two different medications are commonly used to inhibit spontaneous ovulation: either GnRHa agonist or GnRH antagonists. The present study consists of the comparison between the single dose GnRH agonist (Decapeptyl 3,75 IM) and the 7 day dosage of GnRH antagonist (Cetrotide 0,25 mg). The administration of GnRHa is used fundamentally as a long liberation formulation, administered in a single intramuscular injection (IM), which is more practical in terms of use. Nevertheless, the unnecessary persistence and the potentially unfavorable action of GnRHa during the luteal phase and early gestation have questioned its use. The recovery of the Hypophysarian function begins only 8 weeks after the single injection of long liberation of triptorelina 3.75 mg. The GnRH antagonist (Cetrotide 0,25 mg) makes the hypofisary inhibition shorter than with the analogues and can prepare similar endometrium characteristics as a natural cycle. The recipients will be assigned randomly to a group of treatment or another.

Conditions

  • Infertility

Interventions

  • Antagonist GnRH CetrotideDrug

    Cetrotide 0.25 mg. daily/ 7 days

  • Agonist GnRH Acetate TriptorelineDrug

    Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. clinical pregnancy rateTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • IVI Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.